Clinical Trial Update: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial results for asciminib as monotherapy in chronic myeloid leukemia in chronic phase, including patients with and without the T315I mutation, have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Status: COMPLETED | Results posted: 2024-07-12